Technology

SamjinPharmaceutical Selected for ‘World Class Plus’ Program… to Receive Up to 4 Years of R&D Support

Evaluation of Research Projects on Innovative New Drugs, Dosage Forms, and ADC Platform Technologies Pushing for Global Technology Exports Centered on the SJN314 and ADC Platforms

KIM SAE-MI
2026-10-06 14:35:04
SamjinPharmaceutical announced on the 6th that it received a certificate of selection as a new participating company at the “2026 World-Class Plus Project” award ceremony held in Asan, South Chungcheong Province, on the 1st. (Photo: SamjinPharmaceutical)

[Edaily Reporter KIM SAE-MI ] SamjinPharmaceutical(005500)The company has been selected for this government program and will receive research and development (R&D) funding for up to four years.

SamjinPharmaceutical announced on the 6th that it received a certificate of selection as a new participant at the “2026 World Class Plus Project” award ceremony held in Asan, South Chungcheong Province, on the 1st.

The World Class Plus Project is an initiative led by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology (KIAT) that selects mid-sized companies with global growth potential and competitiveness to provide support in areas such as R&D, exports, financing, and consulting.

Previously, in April, SamjinPharmaceutical was selected as a company in the advanced biotechnology sector among 10 mid-sized companies in national high-tech industries, including biotechnology, semiconductors, and future mobility.

According to the company, its proposals for “Advancement of Innovative New Drugs” and “Development of Platform Technologies for Dosage Forms and Antibody-Drug Conjugates (ADCs)” were evaluated in this project based on technical complexity and commercialization potential.

SamjinPharmaceutical is pursuing “SJN314,” a new drug candidate in the immunology and inflammation field, and its ADC platform as core R&D projects. The company plans to pursue global technology exports and phased technology transfers based on these technologies.

Currently, SamjinPharmaceutical has a pipeline of 16 new drug candidates and invests approximately 12% of its revenue in R&D. Going forward, the company intends to expand its collaborative network with global pharmaceutical companies and establish a business structure that links technology exports to commercialization.

Lee Soo-min, Executive Vice President in charge of R&D at SamjinPharmaceutical, stated, “Being selected as a ‘World-Class Company’ is a testament to the recognition of our technological capabilities and global potential, which we have built up over a long period of time.” He added, “We will achieve tangible results in global technology exports and strengthen our competitiveness in the global market by focusing on our core pipelines and platform technologies.”

Economy

Corporation

IT·Science

Economy

Samsung Electro-Mechanics Secures Additional MLCC Orders Worth 285.6 Billion Won… Supply Contracts Estimated at About 4 Trillion Won This Year (Comprehensive)

Samsung Electro-Mechanics has signed a 285.6 billion won supply contract for multilayer ceramic capacitors (MLCCs) with a major global corporation. As demand for high-performance MLCCs is rapidly incr…
2026-10-06 12:08:48

Corporation

From promotional material production to contract review… Companies are cutting outsourcing contracts and hiring 'AI-trained employees'

#Public relations agency A has recently been requiring its employees to take training in “vibe coding” (a method in which a person describes the required functions in natural language, and generative …
2026-10-06 14:32:10

IT·Science

D-1 for the 5th Launch of the Nuri Rocket, Now a “Space Laboratory”… Satellites, Components, and Communication Technologies All on Board

With the fifth launch of the Korean-developed Nuri rocket just one day away, space technologies developed by domestic companies and universities are also drawing attention. With 15 satellites set to b…
2026-10-06 15:02:27